HRP20050843A2 - Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds - Google Patents

Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds

Info

Publication number
HRP20050843A2
HRP20050843A2 HR20050843A HRP20050843A HRP20050843A2 HR P20050843 A2 HRP20050843 A2 HR P20050843A2 HR 20050843 A HR20050843 A HR 20050843A HR P20050843 A HRP20050843 A HR P20050843A HR P20050843 A2 HRP20050843 A2 HR P20050843A2
Authority
HR
Croatia
Prior art keywords
compounds
phenyltetrahydroisoquinolines
medicaments
substituted
production
Prior art date
Application number
HR20050843A
Other languages
Croatian (hr)
Inventor
Hofmeister Armin
Heinelt Uwe
Lang Hans-Jochen
Frick Wendelin
Bleich Markus
Wirth Klaus
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050843A2 publication Critical patent/HRP20050843A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Izum se odnosi na spojeve formule Iu kojoj R1 do R9 imaju značenja navedena patentnim zahtjevima. Lijekovi koji sadrže ovu vrstu spojeva mogu se upotrijebiti za prevenciju ili liječenje raznih bolesti. Ovi spojevi se mogu upotrijebiti, između ostalog, za bolesti bubrega, kao što je akutno ili kronično otkazivanje bubrega, kod poremećaja funkcije žuči, kod respiratornih poremećaja kao što je hrkanje ili apnoje spavanja, ili kod apopleksije.The invention relates to compounds of formula I in which R1 to R9 have the meanings given in the claims. Drugs containing this type of compound can be used to prevent or treat various diseases. These compounds can be used, inter alia, for kidney disease, such as acute or chronic renal failure, in biliary dysfunction, in respiratory disorders such as snoring or sleep apnea, or in apoplexy.

HR20050843A 2003-03-24 2005-09-23 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds HRP20050843A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312963A DE10312963A1 (en) 2003-03-24 2003-03-24 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
PCT/EP2004/002497 WO2004085404A1 (en) 2003-03-24 2004-03-11 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds

Publications (1)

Publication Number Publication Date
HRP20050843A2 true HRP20050843A2 (en) 2006-09-30

Family

ID=32946086

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050843A HRP20050843A2 (en) 2003-03-24 2005-09-23 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds

Country Status (23)

Country Link
EP (1) EP1613600B1 (en)
JP (1) JP2006521306A (en)
KR (1) KR20050115304A (en)
CN (1) CN100364978C (en)
AR (1) AR043741A1 (en)
AU (1) AU2004224242B2 (en)
BR (1) BRPI0408744A (en)
CA (1) CA2519658A1 (en)
DE (1) DE10312963A1 (en)
HK (1) HK1090042A1 (en)
HR (1) HRP20050843A2 (en)
MA (1) MA27751A1 (en)
ME (1) MEP42908A (en)
MX (1) MXPA05010003A (en)
MY (1) MY139498A (en)
NO (1) NO20054876L (en)
NZ (1) NZ542608A (en)
PE (1) PE20050311A1 (en)
RS (1) RS20050713A (en)
RU (1) RU2343147C2 (en)
TW (1) TW200510321A (en)
WO (1) WO2004085404A1 (en)
ZA (1) ZA200506422B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046492A1 (en) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005001411A1 (en) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005033100B3 (en) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation
DE102005044817A1 (en) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102006012544A1 (en) 2006-03-18 2007-09-27 Sanofi-Aventis Substituted 1-amino-4-phenyl-dihydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
CN103159692B (en) * 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 Tetrazole-substituted arylamides
WO2008004610A1 (en) * 2006-07-05 2008-01-10 The University Of Tokyo Method of treating genetic disease caused by nonsense mutation
RU2010151605A (en) * 2008-05-19 2012-06-27 Актелион Фармасьютиклз Лтд (Ch) NEW TETRAHYDROISOCHINOLINS AS ANTI-MALARIAN AGENTS
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2009334511C1 (en) * 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ME02908B (en) * 2011-08-25 2018-10-20 Medicines For Malaria Venture Mmv Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
SI2983667T1 (en) * 2013-04-12 2019-09-30 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
RU2538085C2 (en) * 2013-05-08 2015-01-10 Любовь Демьяновна Шаманская Agent for control of exo-parasites of animals
RU2703456C2 (en) 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Phenyltetrahydroisoquinoline compound, substituted with heteroaryl
MX2019008170A (en) 2017-01-09 2020-02-07 Ardelyx Inc Compounds useful for treating gastrointestinal tract disorders.
MX2019008171A (en) 2017-01-09 2020-02-05 Ardelyx Inc Inhibitors of nhe-mediated antiport.
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7194848B2 (en) * 2019-05-16 2022-12-22 イーライ リリー アンド カンパニー Sodium-Hydrogen Exchanger 3 Inhibitor Compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JPH06256311A (en) * 1993-02-26 1994-09-13 Nippon Shinyaku Co Ltd Isoquinolinol derivative and medicine
DE19951702A1 (en) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Use of 2-amino-3,4-dihydroquinazolines for the manufacture of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
BR0015307A (en) * 1999-11-03 2002-07-09 Albany Molecular Res Inc Compound, composition, pharmaceutical composition, methods to treat a disorder that is created by or is dependent on the decreased availability of serotonin, norepinephrine or dopamine, and to inhibit the absorption of synaptic norepinephrine, synaptic serotonin and synaptic dopamine in a patient in need of these, and together
ATE387429T1 (en) * 1999-11-03 2008-03-15 Amr Technology Inc ARLY- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPPOST INHIBITORS
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
RU2298003C2 (en) * 2001-12-05 2007-04-27 Санофи-Авентис Дойчланд Гмбх Substituted 4-phenyltetrahydroisoquinoline, their using as medicinal agent and medicinal agent comprising thereof
DE10161767A1 (en) * 2001-12-15 2003-06-26 Merck Patent Gmbh New 2-guanidino-4-heterocyclyl-quinazoline derivatives, useful as sodium-proton antiporter subtype III inhibitors for treating e.g. respiratory, renal, ischemic or lipid metabolism disorders
DE10163914A1 (en) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as medicament, and medicament containing them
DE10163992A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-aryl-quinazolines

Also Published As

Publication number Publication date
NZ542608A (en) 2009-07-31
MXPA05010003A (en) 2005-11-17
PE20050311A1 (en) 2005-06-06
CN1798737A (en) 2006-07-05
JP2006521306A (en) 2006-09-21
KR20050115304A (en) 2005-12-07
MA27751A1 (en) 2006-02-01
EP1613600A1 (en) 2006-01-11
CN100364978C (en) 2008-01-30
MEP42908A (en) 2011-02-10
MY139498A (en) 2009-10-30
CA2519658A1 (en) 2004-10-07
EP1613600B1 (en) 2015-12-23
AR043741A1 (en) 2005-08-10
RS20050713A (en) 2007-11-15
ZA200506422B (en) 2007-02-28
AU2004224242A1 (en) 2004-10-07
RU2006127170A (en) 2008-02-10
TW200510321A (en) 2005-03-16
WO2004085404A1 (en) 2004-10-07
NO20054876L (en) 2005-12-06
NO20054876D0 (en) 2005-10-21
RU2343147C2 (en) 2009-01-10
AU2004224242B2 (en) 2010-03-18
HK1090042A1 (en) 2006-12-15
DE10312963A1 (en) 2004-10-07
BRPI0408744A (en) 2006-04-18

Similar Documents

Publication Publication Date Title
HRP20050843A2 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
BR112015018168A2 (en) soft rock inhibitors
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
AR071187A1 (en) ARILMETIL-THIAZINAMINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MEP53608A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
NO20090321L (en) Use of substituted 2-aminotyethralines for the manufacture of a drug for the prevention, relief and / or treatment of various types of pain
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
ATE530524T1 (en) SUBSTITUTED SULFONAMIDE DERIVATIVES
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
ATE524450T1 (en) 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS
BR112014001880A2 (en) substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanyloid receptor ligands
EA200802020A1 (en) TETRAHYDROPYRIMIDAOZEPINA AND THEIR APPLICATION AS TRPV 1 MODULATORS
MX2009004908A (en) Chemical compounds.
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
EA201491606A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
MY150054A (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
BR112014005538A2 (en) aqueous compositions comprising arbecacin
CY1106950T1 (en) S-TENATOPRAZOL Sodium Sodium Monohydrate and Protein Pump Suspension Application
MX2008011204A (en) Substituted 1-amino-4-phenyl-dihydroisoquinolines, method for the production thereof, use thereof as a medicament, and medicaments containing them.
ATE496899T1 (en) TETRAHYDRO- AND DIHYDROQUINAZOLINONES
BRPI0407212A (en) Substituted 2-aminoimidazoles, processes for their preparation, their application as a medicine or diagnosis as well as the medicine containing them
BRPI0407199A (en) unsubstituted (benzoimidazol-2-yl) -phenyl amines, process for their preparation, their application as a medicine or diagnosis and the medicine containing them
WO2007107246A3 (en) SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM
DE502007006951D1 (en) MEDICINAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100309

Year of fee payment: 7

OBST Application withdrawn